Aytu Biopharma Inc expected to post a loss of 32 cents a share - Earnings Preview

Aytu Biopharma

18/09/2026 21:02

Aytu Biopharma Inc AYTU.OQ AYTU.O is expected to  show a fall in quarterly revenue when it reports  results on September 22 for the period ending June 30 2026
The Denver Colorado-based  company is expected to report a 18.9% decrease in revenue to $12.276 million from $15.14 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Aytu Biopharma Inc is for a loss of 32 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.46
-0.51
-0.53
Missed
-3.9
Dec. 31 2026
-0.60
-0.60
-1.05
Missed
-75
Sep. 30 2025
-0.23
-0.23
0.21
Beat
191.3​
Jun. 30 2025
-0.04
-0.04
-2.92
Missed
-7,862.9
​​Mar. 31 2025
-0.17
-0.17
0.21
Beat
223.5
Dec. 31 2024
-0.28
-0.28
-0.26
Beat
7.1​
Sep. 30 2024
-0.34
-0.34
0.44
Beat
229.4
Jun. 30 2024
-0.45
-0.82
Missed
-82.2
This summary was machine generated September 18 at 20:01 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)